rs1553317038
Variant summary
Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PM1PM2PM5PP2PP3_Strong
The NM_014946.4(SPAST):c.1217T>C(p.Ile406Thr) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I406V) has been classified as Pathogenic.
Frequency
Consequence
NM_014946.4 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary spastic paraplegia 4Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Illumina, Genomics England PanelApp, Ambry Genetics
- Charlevoix-Saguenay spastic ataxiaInheritance: AR Classification: DEFINITIVE Submitted by: G2P
- neurodevelopmental disorderInheritance: AD Classification: STRONG Submitted by: G2P
- SPAST-related motor disorderInheritance: AR Classification: STRONG Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 11 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  
GnomAD4 exome Cov.: 28 
GnomAD4 genome  
ClinVar
Submissions by phenotype
Hereditary spastic paraplegia 4    Uncertain:1 
A different missense substitution at this codon (p.Ile406Thr) has been determined to be pathogenic (PMID: 16682546, 19423133, 16476945). This suggests that the isoleucine residue is critical for SPAST protein function and that other missense substitutions at this position may also be pathogenic. In summary, this variant is a novel missense change with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies. This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a SPAST-related disease. This sequence change replaces isoleucine with threonine at codon 406 of the SPAST protein (p.Ile406Thr). The isoleucine residue is highly conserved and there is a moderate physicochemical difference between isoleucine and threonine. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at